{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 88,
  "pageCount": 120,
  "prevPage": 87,
  "nextPage": 89,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/88",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-88",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.66,
        "x": 0.048,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1 Global co-development co-commercial agreement with Pfizer; 2 Global rights licensed to Pfizer; 3 University of Pennsylvania collaboration; 4 Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMGF holds distribution rights.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c586865c-27c4-40ec-959a-f950d97cad37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.905,
        "x": 0.048,
        "y": 0.21
      },
      "kind": "table",
      "text": "Platform, Product candidate, Indication (targets), Next milestone. mRNA vaccines, BNT162b2, COVID-19, Data updates in 2022. Omicron, COVID-19, Data updates in 2022. Omicron + BNT162b2, COVID-19, Data updates in 2022. BNT161, Influenza, Data updates in 2022. Preclinical unnamed program, Shingles, First-in-human trial to start in 2H 2022. BNT163 (prophylactic), HSV2, First-in-human trial to start in 2H 2022. HeTVac (therapeutic), HSV2. BNT164, Tuberculosis, First-in-human trial to start in 2H 2022. BNT165, Malaria, First-in-human trial to start in 2H 2022. Unnamed program, HIV. Ribolysins, Unnamed program, Precision antibacterials.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5a71923-e979-4417-9fec-84c08ab624ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.75,
        "x": 0.048,
        "y": 0.058
      },
      "kind": "title",
      "text": "Expanding opportunities in infectious diseases: 4 first-in-human mRNA vaccine trial starts expected in 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e27d0d7-0071-4791-90fc-5d72b386e685",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}